Latest Regulatory News

Chalice Mining is progressing its Gonneville Project Pre-Feasibility Study on schedule for November 2025 completion, fully funded and targeting a Final Investment Decision by late 2027 as palladium prices hit a two-year high.

Prominence Energy has extended its agreement to acquire the Gawler Hydrogen Project, allowing more time to secure final regulatory approvals and advance exploration in South Australia.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

United States Antimony Corporation has proposed acquiring Larvotto Resources in a deal that could create one of the largest antimony producers outside China, offering Larvotto shareholders a significant premium.

United States Antimony Corporation has made a non-binding indicative offer to acquire Larvotto Resources at a significant premium, proposing a strategic merger focused on antimony supply chain security and growth.

Southern Palladium has raised A$20 million through a strategic share placement to accelerate its Bengwenyama PGM project, positioning the company for key milestones including a Final Investment Decision in 2026.

BMG Resources has addressed recent unusual trading activity, confirming no undisclosed material information and providing an update on its Bullabulling drilling program results.

Jindalee Lithium has launched an options offer linked to its recent Share Purchase Plan and placements, aiming to incentivize shareholders and raise capital for its lithium development projects. The options carry an exercise price of $0.825 and expire in late 2028.

Aurora Energy Metals reports strong metallurgical results and progress toward Eagle Energy Metals’ Nasdaq listing, advancing the Aurora Uranium Project’s development.

Eden Innovations is set to complete the sale of its Georgia industrial property for US$5 million, aiming to significantly reduce its debt burden. The sale proceeds will primarily repay over US$4 million of the company’s iBorrow loan, easing financing costs.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.